fda compounding semaglutide news september 2025 8, 2025: launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines Maybe i’m not against compounding

Description

Common side effects may include: Nausea Diarrhea Vomiting Constipation Abdominal pain Indigestion Injection-site reactions Feeling tired Belching Hair loss Heartburn Rare, but serious side effects may include: Acute pancreatitis (including fatal, hemorrhagic, necrotizing) Acute gallbladder disease Acute kidney injury (typically secondary to dehydration) Severe gastrointestinal disease / delayed gastric emptying Hypoglycemia (especially with insulin or sulfonylureas) Hypersensitivity reactions including anaphylaxis and angioedema Pulmonary aspiration during anesthesia or deep sedation (delayed gastric emptying) Suicidal behavior and ideation (monitor) Diabetic retinopathy complications (in T2D clients with pre-existing retinopathy) Thyroid C-cell tumors (rodent data)

For detailed receptor comparisons including Semaglutide, see our three-compound comparison article

Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis